Counting my change
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks, I just left a message. I will report back as soon as he calls me back.
Hi Cajari,
Could you give me the phone number as I have some questions I would like to ask the CEO. Thanks!
SPPI starting to run broke $5.00,now at $5.10
SPPI Starting to run broke $5.00...@$5.08
BIEL is in Hong Kong working with new distribution partner and then heading to Tokyo.Canada seems to be testing well and as they have announced the Latin American deals have been big winners so far.
Like the article,POZN is primed and ready to go.
On Watch PDMI up 25% with 333,915,660 in volume
as a reminder....
SALT LAKE CITY, UT -- (MARKET WIRE) -- 03/05/10 -- Paradigm Medical Industries, Inc. (PINKSHEETS: PDMI) announced today that it has been notified by its Italian partner, Costruzione Strumenti Oftalmici (CSO), that all necessary documents have been completed and submitted to the United States Food and Drug Administration (FDA) for the Retimax?, also known as the Paramax. Paradigm is the exclusive representative for this significant new product in the U.S. market. "This new innovative device offers the earliest detection of glaucoma currently available and will be an excellent addition to Paradigm's glaucoma diagnostic products," said Stephen Davis, Paradigm's President and Chief Executive Officer.
The Paramax (as it will be known in the United States) represents the third product that Paradigm represents for CSO. Paradigm also represents CSO's impressive corneal topographer, to be known in the U.S. as the Paravue 300, and CSO's corneal topographer with Scheimpflug rotating camera, to be known in the U.S. as the Surveyor 500. The Surveyor 500 with the Scheimpflug camera allows for the complete analysis of the entire cornea and anterior segment of the eye. Paradigm plans to begin active promotion of the Paravue 300 and the Surveyor 500 and will actively promote the Paramax immediately after it has received FDA approval.
Great post ,Thanks!
2500 now,but he holds over 17000 shares direct that is about $84,000 of his own money out there.Nobody like to risk their own money unless they feel there is money to be made.
SPPI Insider buying Form 4 Link
http://moneycentral.msn.com/investor/sec/filing.asp?Symbol=sppi
Added shares of POZN @ $10.10 End of April will be a strong month as we move to the PDUFA date of April 30th for Vimovo
SPPI NEWS!..Dir Fulmer buys $4000.00 @ $4.83 for a total of 21,000 Direct
The IBox has been updated with a lot of Information and Videos!!
Thanks, LACO! Has not always been easy to have management call me back,but so far so good.Will keep on it.
Thanks, PIE! You have been great!
That is true....they will be upgrading internet ordering on their site.
AEMD NEWS UPDATE
Press Release Source: RedChip Companies Inc. On Friday April 16, 2010, 9:41 am EDT
ORLANDO, Fla., April 16, 2010 (GLOBE NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., has issued a research update on Aethlon Medical, Inc. (OTCBB:AEMD - News), a company developing a therapeutic device to treat acute and chronic viral infections, biological warfare pathogens, and other conditions by filtering virus particles and immunosuppressive agents from the blood.
David Webber, RedChip Research Analyst, reported:
"During the early months of 2010, Aethlon advanced its core Hepatitis C program with manufacturing progress and steps towards early commercialization in India and helped lay the groundwork for studies in exosomes, which could lead to use in the treatment of certain types of cancer."
"Aethlon has moved to a strategy that focuses on early commercialization in India, where the market would be a mix of medical tourists and Indian citizens. As we believe that the Company at this point could not afford to do the sort of clinical trials needed for U.S. or EU approvals, the Indian strategy appears to make sense as a means to increase real-world experience with the Hemopurifier in HCV therapy while offsetting expenses with sales revenues."
"In our opinion, commercialization in India would increase the clinical database and, assuming positive patient outcomes, improve the odds for a development and marketing partnership, a likely necessity for eventual commercialization in the United States and/or Europe. The probability of these steps has increased in recent months through a favorable classification of the Hemopurifier by the Indian authorities and work to develop treatment protocols for HCV patients in India."
"In addition, the Company completed a successful pilot production run under Good Manufacturing Practices (GMP) standards, a Food & Drug Administration (FDA) requirement for device export, and reached a tentative commercial manufacturing contract with Membrana GmbH, a global leader in hollow fiber filter technology and production."
Webber continued, "We rate Aethlon Medical a Speculative Buy with a 12-month price target of $1.00 per share. We expect the chief driver of the stock over the next year to be steps towards commercialization for the treatment in India."
To receive a complimentary copy of the RedChip Visibility Research Update for AEMD, please visit: http://www.redchip.com/about/aboutmain.asp?rid=230
To learn more about Aethlon, visit http://www.redchip.com/visibility/investor.asp?symbol=AEMD.
About Aethlon Medical
Aethlon Medical, Inc. creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our lead product, the Hemopurifier(R), is the first-in-class medical device to selectively capture circulating viruses and immunosuppressive proteins prior to cell and organ infection. Human studies have documented the ability of our Hemopurifier(R) to reduce viral load in patients infected with the Hepatitis C Virus (HCV) and the Human Immunodeficiency Virus (HIV). Our primary clinical and commercialization focus is to establish the Hemopurifier(R) as an adjunct therapy to enhance and prolong the benefit of traditional infectious disease drug regimens.
The Hemopurifier(R) is also a broad-spectrum treatment candidate against drug resistant bioterror and pandemic threats. Third party research institutes have verified the capability of the device to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
Exosome Sciences, Inc. (ESI) was formed in October of 2009 to leverage attributes of the Hemopurifier(R) in the emerging exosome research field. ESI seeks to inhibit the immune cell destruction caused by exosomes secreted by solid tumors, lymphomas, and leukemia. At present, the capture of immunosuppressive exosomes secreted from ovarian cancer tumors has been demonstrated invitro. The preservation of anti-cancer immune cells would likely improve patient responsiveness to established treatment options, including immunotherapy and chemotherapy. ESI is also analyzing exosome-related opportunities to improve early cancer detection and post-surgery surveillance of tumor growth, as well as approaches to harvest exosomes for research purposes and potential reintroduction into patients afflicted with autoimmune conditions such as Rheumatoid Arthritis and Lupus.
Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at http://www.aethlonmedical.com/.
About RedChip Companies, Inc.
RedChip Companies is an international, small-cap research and financial public relations firm headquartered in Orlando, Florida with affiliate offices in Qingdao, China; Paris and San Diego. RedChip delivers concrete, measurable results for its clients through its extensive national and international network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research(TM), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, RedChip Small-Cap TV(TM), Shareholder Intelligence, Social Media and Blogging Services, Webcasts, and RedChip Radio(TM). To learn more about RedChip's products and services .please visit: http://www.redchip.com/visibility/productsandservices.asp.
"Discovering Tomorrow's Blue Chips Today"(TM)
The RedChip Companies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2761
Disclosure
The analysts contributing to this report do not hold any shares of Aethlon Medical, Inc. (AEMD). RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. The equity research report(s) are not a recommendation of a solicitation to purchase or sell any security, nor do they constitute investment advice. AEMD is a client of RedChip Companies, Inc. and of RedChip Visibility, a division of RedChip Companies. AEMD paid RedChip Visibility, a division of RedChip Companies, Inc., one hundred thousand shares of Rule 144 common stock for RedChip Visibility Program services, which includes the preparation of the equity research report(s). The equity research report(s) are prepared for informational purposes only and are paid for by the company portrayed in the report. Information contained in the equity research report(s) is obtained from sources believed to be reliable, but their accuracy and completeness are not guaranteed. RedChip Companies, Inc. is currently engaged by this company to provide investor awareness services. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. These services may include investor conferences, digital and print distribution of AEMD investor-related materials, investor road shows and radio programming. AEMD agreed to pay RedChip Companies, Inc. three hundred thousand shares of Rule 144 common stock for six months of these investor relations services. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein.
Contact:
RedChip Companies, Inc.
1-800-RED-CHIP (733-2447, Ext. 106)
research@redchip.com
http://www.RedChip.com
Alert... POZN ($9.99)great entry point to get in or add. Run will start soon going into approval.
ADVENTRX Resolves NYSE Amex Listing Deficiencies
Plans Reverse Stock Split to Address Exchange's Low Stock Price Concern
prnewswire
Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Friday April 16, 2010, 8:00 am
SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has resolved the stockholders' equity continued listing deficiencies originally identified by the NYSE Amex in a June 2009 letter to the Company. In part to address the NYSE Amex's requirement that the Company address its low stock price, ADVENTRX also announced that its Board of Directors has approved a 1-for-25 reverse split of its common stock, which was authorized by its stockholders at a special meeting held in August 2009. The Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010.
In June 2009, the NYSE Amex notified the Company that it was not in compliance with the NYSE Amex's continued listing standards related to stockholders' equity. Through financing activity in 2009, ADVENTRX increased its stockholder's equity to approximately $6.7 million as of December 31, 2009, which exceeds continued listing standards related to stockholders' equity. In April 2010, the NYSE Amex notified the Company that, based on a review of publicly available information, ADVENTRX has resolved the continued listing deficiencies originally identified in the June 2009 letter. According to the April 2010 letter, the Company must demonstrate compliance with the continued listing standards for two consecutive quarters and/or by December 1, 2010, otherwise the NYSE Amex may initiate delisting procedures. In part as a result of a financing completed in January 2010, the Company anticipates complying with continued listing standards related to stockholders' equity at March 31, 2010.
The reverse stock split is intended to satisfy the NYSE Amex's determination in the June 2009 letter that it is appropriate for the Company to effect a reverse stock split to address its low price per share and that, if a reverse stock split is not completed within a reasonable amount of time, the NYSE Amex may initiate delisting procedures. The Company also believes that a higher share price could broaden ADVENTRX's appeal to investors, in addition to reducing per share transaction fees and certain administrative costs.
The reverse split will be effective upon the close of trading on Friday, April 23, 2010, and the Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010. The reverse split will reduce the number of shares of the Company's common stock outstanding from approximately 257 million to approximately 10.3 million. Proportional adjustments will be made to ADVENTRX's outstanding stock options, warrants and other equity awards and to its equity compensation plans. Par value and the number of authorized shares of common stock will not change. The Company will not issue any fractional shares. Stockholders will receive cash in lieu of fractional shares to which they would otherwise be entitled.
Information for Stockholders regarding Reverse Stock Split
Registered holders of ADVENTRX common stock will receive a letter of transmittal shortly after the effective date of the reverse stock split with instructions for the exchange of their old stock certificates or the electronic adjustment of their holdings through the direct registration system, as applicable. American Stock Transfer and Trust Company will act as the exchange agent and can be contacted at (877) 2486417. Stockholders with shares in brokerage accounts will be contacted by their brokers with instructions.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will not meet the NYSE Amex's stockholders' equity continued listing standards for two consecutive quarters and/or by December 1, 2010 and that the NYSE Amex staff will commence delisting proceedings; the risk of negative market reaction following announcement and/or implementation of the planned reverse stock split, resulting in stock price decline; the risk of unexpected delays in completing the reverse stock split; the risk that NYSE Amex will commence delisting proceedings based on a future low selling price per share; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which it is able to comply with NYSE Amex continued listing requirements related to stockholders' equity; the risk that ADVENTRX will be unable to raise sufficient additional capital to continue to develop, seek regulatory approval of and commercialize its product candidates while maintaining compliance with NYSE Amex continued listing requirements related to stockholders' equity; the risk of difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ADVENTRX's lead product candidates; ADVENTRX's reliance on the performance of third parties to assist in the conduct of its bioequivalence trials, regulatory submissions, CMC activities and other important aspects of its product candidate development programs, and that such third parties may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2009. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.
Company Contact:
ADVENTRX Pharmaceuticals
Brian Culley, Chief Executive Officer
858-552-0866
Investor Contact:
Lippert/Heilshorn & Associates, Inc.
Don Markley (dmarkley@lhai.com)
310-691-7100
PIE,I agree not a bad day.Management told me that it will keep up the communication with it shareholders better,in the form of PRs(which they are).
I agree.. I tried this product running it thru all kinds of testing and have never seen another product like it in its class.This company is under radar,but not for long!
SPPI keeps climbing...closed at $5.00
ANX on the move!last week April FDA news expected.
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it will meet the U.S. Food and Drug Administration (FDA) in Washington D.C. during the last week of April 2010 to review the Company's New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion) and the FDA's refusal-to-file letter.
ADVENTRX had requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.
"We look forward to meeting with the agency next month to clarify the necessary steps for filing the ANX-530 NDA this year," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009. The Company announced on March 1, 2010 that it had received a refusal-to-file letter from the FDA regarding that submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. No clinical or nonclinical issues were identified.
ANX on the move! last week April FDA news expected.
Remember...
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it will meet the U.S. Food and Drug Administration (FDA) in Washington D.C. during the last week of April 2010 to review the Company's New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion) and the FDA's refusal-to-file letter.
ADVENTRX had requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.
"We look forward to meeting with the agency next month to clarify the necessary steps for filing the ANX-530 NDA this year," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009. The Company announced on March 1, 2010 that it had received a refusal-to-file letter from the FDA regarding that submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. No clinical or nonclinical issues were identified.
ThermaFreeze Products Now Available in Duane Reade Stores -- New York's Largest Drugstore Operator; Initial Sales Encouraging
marketwire
Press Release Source: ThermaFreeze Products Corp On Thursday April 15, 2010, 10:04 am EDT
MOBILE, AL--(Marketwire - 04/15/10) - ThermaFreeze Products Corporation (Pinksheets:TZPC - News), the maker of patented, innovative refrigerant products designed for use as a consumer compress and chiller product and for use in the commercial shipment of perishables, today announced it has successfully launched retail distribution into New York City's largest drugstore chain, Duane Reade. The ThermaFreeze ice sheets are now available within the seasonal sales section in over 200 Duane Reade stores.
"Our retail distribution is growing very quickly, which will lead to growing revenues for the Company," commented Tony Trezza, Vice President of Sales for ThermaFreeze Products Corporation. "We are particularly pleased with our success at Duane Reade as the products are being prominently displayed at eye level in the high traffic seasonal sales area. We have been monitoring initial sales and we are very pleased with the results at both Duane Reade and at other retailers. It is clearly a very exciting time for all of us at ThermaFreeze and for our shareholders as we continue expanding into retail distribution throughout the country."
About ThermaFreeze Products Corporation
ThermaFreezeâ„¢ Products Corporation manufactures and markets a patented, innovative refrigerant product designed for use as a consumer compress and chiller product and for use in the commercial shipment of perishables. ThermaFreezeâ„¢ refrigerant is flat, lightweight and flexible even when frozen, making it more convenient and cost-effective than ice, gel packs, ice bricks and dry ice.
Safe Harbor for Forward-Looking Statements
Statements made in this release with the respect to the Company's current plans, estimates, strategies and beliefs and other statements that are not historical are forward-looking statements. Forward-looking statements include, but are not limited to, those statements using words such as "believe," "expect" and "plans" and words of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. Statements are based on management's assumptions and beliefs in light of the currently available information. The Company cautions that a number of important risks and uncertainties could cause actual results to materially differ from those discussed in the forward-looking statements, and therefore, undue reliance should not be placed on them.
Contact:
Contact:
ThermaFreeze Products Corporation
Joe Noel
(925) 922-2560
CORRECTING and REPLACING Neoprobe to Present at Future Leaders in Biotech Conference
businesswire
Press Release Source: Neoprobe Corporation On Monday April 12, 2010, 3:49 pm EDT
DUBLIN, Ohio--(BUSINESS WIRE)--Webcast link in third graph of release dated April 1, 2010, should read: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2957639 (sted http://www.corporateir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2957639).
The corrected release reads:
NEOPROBE TO PRESENT AT FUTURE LEADERS IN BIOTECH CONFERENCE
Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that its President and CEO, David Bupp, will present at the upcoming Future Leaders in the Biotech Industry conference on April 8, 2010, at 4:30 p.m. The conference is being held at the Millennium Broadway Hotel in New York City.
Hosted by BioCentury and Thomson Reuters, Future Leaders in the Biotech Industry showcases companies best positioned to provide market leadership in the biotech industry. Mr. Bupp will provide a corporate overview, including an update and discussion of the clinical and regulatory status of Neoprobe’s two drug development products, Lymphoseek® and RIGScanâ„¢ CR.
A live audio webcast of this presentation and copy of the presentation slides will be available at:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2957639
A replay of the presentation will also be available at the same site following the live webcast.
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScanâ„¢ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com
Contact:
Neoprobe Corporation
Brent Larson, 614-822-2330
Vice President / CFO
or
The Shoreham Group
Tim Ryan, 212-242-7777
Buzz up! 6
Send
Share
Print
CORRECTING and REPLACING Neoprobe to Present at Future Leaders in Biotech Conference
businesswire
Press Release Source: Neoprobe Corporation On Monday April 12, 2010, 3:49 pm EDT
DUBLIN, Ohio--(BUSINESS WIRE)--Webcast link in third graph of release dated April 1, 2010, should read: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2957639 (sted http://www.corporateir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2957639).
The corrected release reads:
NEOPROBE TO PRESENT AT FUTURE LEADERS IN BIOTECH CONFERENCE
Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that its President and CEO, David Bupp, will present at the upcoming Future Leaders in the Biotech Industry conference on April 8, 2010, at 4:30 p.m. The conference is being held at the Millennium Broadway Hotel in New York City.
Hosted by BioCentury and Thomson Reuters, Future Leaders in the Biotech Industry showcases companies best positioned to provide market leadership in the biotech industry. Mr. Bupp will provide a corporate overview, including an update and discussion of the clinical and regulatory status of Neoprobe’s two drug development products, Lymphoseek® and RIGScanâ„¢ CR.
A live audio webcast of this presentation and copy of the presentation slides will be available at:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2957639
A replay of the presentation will also be available at the same site following the live webcast.
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScanâ„¢ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com
Contact:
Neoprobe Corporation
Brent Larson, 614-822-2330
Vice President / CFO
or
The Shoreham Group
Tim Ryan, 212-242-7777
Buzz up! 6
Send
Share
Print
CORRECTING and REPLACING Neoprobe to Present at Future Leaders in Biotech Conference
businesswire
Press Release Source: Neoprobe Corporation On Monday April 12, 2010, 3:49 pm EDT
DUBLIN, Ohio--(BUSINESS WIRE)--Webcast link in third graph of release dated April 1, 2010, should read: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2957639 (sted http://www.corporateir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2957639).
The corrected release reads:
NEOPROBE TO PRESENT AT FUTURE LEADERS IN BIOTECH CONFERENCE
Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that its President and CEO, David Bupp, will present at the upcoming Future Leaders in the Biotech Industry conference on April 8, 2010, at 4:30 p.m. The conference is being held at the Millennium Broadway Hotel in New York City.
Hosted by BioCentury and Thomson Reuters, Future Leaders in the Biotech Industry showcases companies best positioned to provide market leadership in the biotech industry. Mr. Bupp will provide a corporate overview, including an update and discussion of the clinical and regulatory status of Neoprobe’s two drug development products, Lymphoseek® and RIGScanâ„¢ CR.
A live audio webcast of this presentation and copy of the presentation slides will be available at:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NEOP&item_id=2957639
A replay of the presentation will also be available at the same site following the live webcast.
About Neoprobe
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScanâ„¢ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com
Contact:
Neoprobe Corporation
Brent Larson, 614-822-2330
Vice President / CFO
or
The Shoreham Group
Tim Ryan, 212-242-7777
Buzz up! 6
Send
Share
Print
PIE,With a day like this I might be able to buy you some vegi spread!
Somebody has to feed the economy!!
At the shows,I was also told that Paul does not let anyone leave without buying a jar or two. These boys are aggressive.
Yesterday
Laco,
They will be doing just that,per a previous conversation with management. They are also doing it at the food shows as well as selling jars. I talked to management about getting into the Trader Joe's chain,which would be a perfect match.
Bid 1 2@.0098 1@.0097 Ask 1@.01 3@.011
PIE.. It is finally coming together!
This is enormous patience prevails!
Alert News!..Nature's Peak Announces It Is Now Accepting Consumer Orders Through Its Website
Nature's Peak will now begin accepting consumer orders directly through its website at www.NaturesPeak.com
prnewswire
Press Release Source: Nature's Peak / Everock, Inc. On Wednesday April 14, 2010, 8:00 am
SANTA CRUZ, Calif., April 14 /PRNewswire-FirstCall/ -- Nature's Peak / Everock, Inc. (Pink Sheets:EVRN.pk - News) announced today that it will now begin accepting consumer orders directly through its website for delivery in May.
Paul Wilkinson, CEO of Nature's Peak / Everock, said, "As we begin to fill orders for distributors and retailers in May we will now start accepting orders directly from consumers. We will fill the consumer orders in May right along side and with the distributor's orders."
Shoppers will be able to put together a selection of personal favorites from the entire line of VeggieDip and VeggieSpread varieties. There is no minimum order size so consumers can order a single jar or a multi-jar sampler pack. We are excited that folks who want our delicious vegetable dips and spreads can now enjoy them wherever they live.
Wilkinson continued, "This is part of our 2010 roll-out. We believe that getting the product in the hands of the consumers is a proactive step in supporting our sales efforts. It will help us further develop consumer awareness of the Nature's Peak brand, which will in turn assist in our retailer and distributor placement."
About Nature's Peak / Everock:
Nature's Peak produces a line of all-natural gourmet vegetable dips and sandwich spreads marketed under the Nature's Peak brand.
Both VeggieDip and VeggieSpread are 100% all-natural, vegetarian, Kosher and gluten-free, and contain no preservatives, artificial ingredients, trans-fats, or sugars. There are six flavors in each product line, including novel delicious flavor combinations.
Nature's Peak products are marketed through its Master Broker to natural food stores, specialty groceries as well as regional and national grocery chains. Our products will also be available to restaurants, delis and other food service providers across America.
Visit our website at www.NaturesPeak.com to learn more about our products and to discover new and delicious recipe ideas.
Forward Looking Statements:
This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The Company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These statements are identified as any statement that does not relate strictly to historical or current facts. They use words such as "anticipates," "intends," "plans," "expects," "will," and other words and phrases of similar meaning. In all cases, a broad variety of assumptions can affect the realization of the expectations or forecasts in those statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, the Company's ability to develop operations, the Company's ability to consummate and complete an acquisition, the Company's access to future capital, the successful integration of acquired companies, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, sales and other factors that may be identified from time to time in the Company's public announcements. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially.
This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.
No more
The Whole Foods order is an extremely big deal. Whole Foods is a very hard account to get.They must of felt the product had a lot of potential and if successful this smaller order will turn into a massive one.Do you know how many companies would die to get into Whole Foods? This is a huge milestone.
I feel your pain!